Article in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 1 institution in 1 country.
Verginia C Cuzon CarlsonDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Carlos F AylwinDivision of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Timothy L CarlsonDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Matthew FordDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Houda MesnaouiDivision of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Alejandro LomnicziDivision of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Betsy FergusonDivision of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Rita P Cervera-JuanesDivision of Genetics, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-0001-3640
Oregon National Primate Research Center · US
Funding
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Translational measures of risk for excessive alcohol consumptionP60AA010760 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI TAMARA J. PHILLIPS · 2006 to 2026
$34.5M
Monkey Alcohol Tissue Research Resource (MATRR)R24AA019431 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mary Lauren Benton, Verginia Carmella Cuzon Carlson · 2010 to 2026
$10.3M
Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
Distinguishing preexistent and induced epigenetic risk for alcohol use disordersR01AA026278 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CERVERA JUANES, RITA P · 2019 to 2023
$3.2M
Metabolic Control of Puberty: Epigenetic LinksR01HD084542 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI LOMNICZI, ALEJANDRO · 2015 to 2019
$2.6M
Identifying new targets for the treatment of alcohol dependence and relapse: epigenetic analysis of the abstinent brainR01AA027552 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CERVERA JUANES, RITA P · 2020 to 2024
$2.6M
GDNF gene therapy to block relapse of heavy alcohol use in monkeysR01AA024757 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI FORD, MATTHEW M · 2016 to 2018
$1.5M
Alcohol-associated DNA Methylation in the Primate BrainR03AA026092 · NIAAA · OREGON HEALTH & SCIENCE UNIVERSITY · PI CERVERA JUANES, RITA P · 2018 to 2019
Hazardous, heavy drinking increases risk for developing alcohol use disorder (AUD), which affects ~7% of adult Americans. Thus, understanding the molecular mechanisms promoting risk for heavy drinking is essential to developing more effective AUD pharmacotherapies than those currently approved by the FDA. Using genome-wide bisulfate sequencing, we identified DNA methylation (DNAm) signals within the nucleus accumbens core (NAcC) that differentiate nonheavy and heavy ethanol-drinking rhesus macaques. One differentially DNAm region (D-DMR) located within the gene neurobeachin (NBEA), which promotes synaptic membrane protein trafficking, was hypermethylated in heavy drinking macaques. A parallel study identified a similar NBEA D-DMR in human NAcC that distinguished alcoholic and nonalcoholic individuals. To investigate the role of NBEA in heavy ethanol drinking, we engineered a viral vector carrying a short hairpin RNA (shRNA) to reduce the expression of NBEA. Using two murine models of ethanol consumption: 4 days of drinking-in-the-dark and 4 weeks of chronic intermittent access, the knockdown of NBEA expression did not alter average ethanol consumption in either model. However, it did lead to a significant increase in the ethanol preference ratio. Following withdrawal, whole-cell patch clamp electrophysiological experiments revealed that Nbea knockdown led to an increase in spontaneous excitatory postsynaptic current amplitude with no alteration in spontaneous inhibitory postsynaptic currents, suggesting a specific role of NBEA in trafficking of glutamatergic receptors. Together, our findings suggest that NBEA could be targeted to modulate the preference for alcohol use.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Neurobeachin, a promising target for use in the treatment of alcohol use disorder. · full record | OpenQuestion